Ghent University Academic Bibliography

Your filters: cql: author="De Meerleer, Gert" or (type any "bookEditor issueEditor" and editor="De Meerleer, Gert")

Add to list
- Conference Paper
- C3
Adjuvant EBRT for muscle-invasive bladder cancer : phase 2 trial secondary analysis (NCT02397434)

Flor Verghote (UGent) , Piet Dirix, Charles Van Praet (UGent) , Charlien Berghen, Ben Vanneste (UGent) , Sara Junius, Nick Liefhooghe, Leen Noé, Gert De Meerleer, Piet Ost (UGent) , et al.

(2024) RADIOTHERAPY AND ONCOLOGY. In Radiotherapy and Oncology 194(Supplement 1). p.S2308-S2311
Add to list
- Journal Article
- A1
- open access
Evaluating the impact of prostate only versus pelvic radiotherapy for pathological node-positive prostate cancer : first results from the multicenter phase 3 PROPER trial

Valerie Fonteyne (UGent) , Charles Van Praet (UGent) , Piet Ost (UGent) , Siska Van Bruwaene, Nick Liefhooghe, Charlien Berghen, Gert De Meerleer, Ben Vanneste (UGent) , Caroline Verbaeys, Sofie Verbeke, et al.

(2023) EUROPEAN UROLOGY FOCUS. 9(2). p.317-324
Add to list
- Journal Article
- A1
- open access
High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer

Nuradh Joseph, Alessandro Cicchetti, Alan McWilliam, Adam Webb, Petra Seibold, Claudio Fiorino, Cesare Cozzarini, Liv Veldeman (UGent) , Renée Bultijnck (UGent) , Valerie Fonteyne (UGent) , et al.

(2022) FRONTIERS IN ONCOLOGY. 12.
Add to list
Progression-directed therapy for oligoprogression in castration-refractory prostate cancer

Charlien Berghen, Steven Joniau, Piet Ost (UGent) , Kenneth Poels, Wouter Everaerts, Karel Decaestecker (UGent) , Karin Haustermans, Gaëtan Devos and Gert De Meerleer

(2021) EUROPEAN UROLOGY ONCOLOGY. 4(2). p.305-309
Add to list
A fatal wound complication following sequential anti-angiogenesis, immune checkpoint inhibition and ultra-hypofractionated radiotherapy

Miha Orazem, Cedric Draulans, Mathieu Spaas (UGent) , Eric Van Cutsem, Marina Debecker, Gert De Meerleer, Sabine Tejpar, Jeroen Dekervel and Karin Haustermans

(2021) CLINICAL JOURNAL OF GASTROENTEROLOGY. 14(4). p.1121-1125
Add to list
- Journal Article
- A1
- open access
Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC) : a phase II prospective trial

Flor Verghote (UGent) , Lindsay Poppe (UGent) , Sofie Verbeke (UGent) , Piet Dirix, Maarten Albersen, Gert De Meerleer, Charlien Berghen, Piet Ost (UGent) , Geert Villeirs (UGent) , Pieter De Visschere (UGent) , et al.

(2021) BMC CANCER. 21(1).
Add to list
- Journal Article
- A1
- open access
Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity

Nicola Rares Franco, Michela Carlotta Massi, Francesca Ieva, Andrea Manzoni, Anna Maria Paganoni, Paolo Zunino, Liv Veldeman (UGent) , Piet Ost (UGent) , Valerie Fonteyne (UGent) , Christopher J. Talbot, et al.

(2021) RADIOTHERAPY AND ONCOLOGY. 159. p.241-248
Add to list
- Journal Article
- A1
- open access
A trial-based cost-utility analysis of metastasis-directed therapy for oligorecurrent prostate cancer

Elise De Bleser, Ruben Willems (UGent) , Karel Decaestecker (UGent) , Lieven Annemans (UGent) , Aurélie De Bruycker, Valerie Fonteyne (UGent) , Nicolaas Lumen (UGent) , Filip Ameye, Ignace Billiet, Steven Joniau, et al.

(2020) CANCERS. 12(1).
Add to list
- Journal Article
- A1
- open access
A deep learning approach validates genetic risk factors for late toxicity after prostate cancer radiotherapy in a REQUITE Multi-National Cohort

Michela Carlotta Massi, Francesca Gasperoni, Francesca Ieva, Anna Maria Paganoni, Paolo Zunino, Andrea Manzoni, Nicola Rares Franco, Liv Veldeman (UGent) , Piet Ost (UGent) , Valerie Fonteyne (UGent) , et al.

(2020) FRONTIERS IN ONCOLOGY. 10.
Add to list
Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial

Elke Rammant (UGent) , Piet Ost (UGent) , Martijn Swimberghe (UGent) , Barbara Vanderstraeten (UGent) , Nicolaas Lumen (UGent) , Karel Decaestecker (UGent) , Renée Bultijnck (UGent) , Gert De Meerleer, Camille Sarrazyn, Roos Colman (UGent) , et al.

(2019) STRAHLENTHERAPIE UND ONKOLOGIE. 195(5). p.393-401

Academic Bibliography

Adjuvant EBRT for muscle-invasive bladder cancer : phase 2 trial secondary analysis (NCT02397434)

Evaluating the impact of prostate only versus pelvic radiotherapy for pathological node-positive prostate cancer : first results from the multicenter phase 3 PROPER trial

High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer

Progression-directed therapy for oligoprogression in castration-refractory prostate cancer

A fatal wound complication following sequential anti-angiogenesis, immune checkpoint inhibition and ultra-hypofractionated radiotherapy

Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC) : a phase II prospective trial

Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity

A trial-based cost-utility analysis of metastasis-directed therapy for oligorecurrent prostate cancer

A deep learning approach validates genetic risk factors for late toxicity after prostate cancer radiotherapy in a REQUITE Multi-National Cohort

Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial

Contents

Support

Contact